Short chain fatty acids modulate nuclear receptor and extranuclear L-triiodothyronine levels in glial C6 cells by different mechanisms.
After incubation with [125]T3, the amount of radioactivity associated with the nuclear receptor and extranuclear compartment increases in glial C6 cells previously exposed to millimolar concentrations of butyrate. These actions of the fatty acid are accompanied by an inhibition of cell division, as shown by the decrease in [3H]thymidine incorporation or total DNA content per culture. Isobutyrate produced a similar effect at concentrations higher than 2 mM, whereas between 0.5-2 mM it increased the receptor content without affecting either extra-nuclear hormone or DNA. For both fatty acids there was a close parallelism between the dose-response curve for the inhibition of turnover of [3H]acetate from the histones and the increase in receptor levels. In contrast, a different dose dependence was found for the increase in extranuclear T3 levels, which suggests that the latter is caused by a mechanism other than histone acetylation. The increase in extranuclear T3 levels correlated better with the decrease in DNA and the accumulation of the chromosomal protein H10, which is thought to be related to the inhibition of cell proliferation. This suggests a relationship between the increase in extranuclear T3 and the inhibition of DNA synthesis. However, other agents, such as glucocorticoids or cAMP, which also inhibit C6 cell proliferation, were ineffective in increasing not only the receptor but also the extranuclear hormone. These findings show that the effect of short chain fatty acids on the receptor is not a consequence of the inhibition of cell replication, and that this inhibition could be related to, but is not sufficient per se for causing the increase in extranuclear T3.
Ortiz-Caro
J
J
Unidad de Endocrinologia Experimental, Universidad Autonoma de Medicina, Madrid, Spain.
Montiel
F
F
Yusta
B
B
Pascual
A
A
Aranda
A
A
D000085:Acetates / Q000378:metabolism; D019342:Acetic Acid; D002087:Butyrates / Q000008:administration & dosage / Q000494:pharmacology; D020148:Butyric Acid; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D002467:Cell Nucleus / Q000378:metabolism*; D000242:Cyclic AMP / Q000502:physiology; D004247:DNA / Q000096:biosynthesis; D003907:Dexamethasone / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005232:Fatty Acids, Volatile / Q000494:pharmacology*; D006657:Histones / Q000378:metabolism; D058610:Isobutyrates; D009457:Neuroglia / Q000187:drug effects / Q000378:metabolism*; D011988:Receptors, Thyroid Hormone / Q000378:metabolism*; D014284:Triiodothyronine / Q000378:metabolism*
D000085:Acetates; D002087:Butyrates; D005232:Fatty Acids, Volatile; D006657:Histones; D058610:Isobutyrates; D011988:Receptors, Thyroid Hormone; D014284:Triiodothyronine; D020148:Butyric Acid; D003907:Dexamethasone; C020380:isobutyric acid; D004247:DNA; D000242:Cyclic AMP; D019342:Acetic Acid